Abbott (ABT) Stock Completes $21B Exact Sciences (EXAS) Acquisition

TLDR

• Abbott completed its $21 billion acquisition of Exact Sciences on March 23, 2026
• EXAS shareholders received $105.00 per share in cash
• Exact Sciences is now a wholly owned subsidiary of Abbott (ABT)
• EXAS was delisted from Nasdaq; March 20 was the last day of trading
• All Exact Sciences board members and officers resigned at the close of the merger

Exact Sciences (EXAS) shareholders had a good run. The stock climbed nearly 130% over the past year before Abbott came knocking — and now the chapter is officially closed.

Exact Sciences Corporation, EXAS

Abbott Laboratories completed its acquisition of Exact Sciences on March 23, 2026. The deal was finalized through a merger with Badger Merger Sub I, Inc., a wholly owned subsidiary of Abbott.

Every outstanding share of Exact Sciences common stock was converted into the right to receive $105.00 in cash. Dissenting and certain excluded shares were not part of the conversion.

The total deal value came in at approximately $21 billion, funded through a mix of cash on hand and debt financing. That figure could rise slightly depending on the conversion of outstanding convertible notes.

Before the deal closed, Exact Sciences carried a market cap of around $20 billion. The company had posted a loss of $1.10 per share over the last twelve months on revenue of $3.25 billion. Analysts had projected a profit of $1.27 per share for the current year.

Delisting and Trading Halt

Trading of EXAS on Nasdaq was halted before the market opened on Monday, March 23. March 20, 2026, was the final day of regular trading for Exact Sciences stock.

Exact Sciences has notified Nasdaq of the completed transaction and formally requested the delisting of its common stock. The company also plans to file to suspend its SEC reporting obligations.

What Happened to Employee Awards and Notes

Outstanding convertible notes held by Exact Sciences investors will now be convertible solely into cash. The conversion is based on existing rates and the $105.00 per share merger price.

All stock options, restricted stock units, deferred stock units, and performance share units under Exact Sciences’ stock plans were handled as part of the merger. They were either converted into the right to receive cash or assumed by Abbott with revised terms.

At the close of the merger, all members of the Exact Sciences board of directors and its officers resigned from their positions.

The company’s certificate of incorporation and bylaws were also amended and restated in connection with the deal.

Shareholders had approved the merger earlier, with 67.56% of eligible votes cast in favor of the agreement.

All required regulatory approvals had been secured ahead of the March 23 closing date.

Abbott stated the acquisition positions it as a leader in cancer screening and diagnostics, expanding its reach to millions of additional patients.

Federal legislation was also recently passed to establish a Medicare coverage pathway for multi-cancer early detection tests — a development Exact Sciences had flagged as a key milestone in cancer detection ahead of the deal closing.

The post Abbott (ABT) Stock Completes $21B Exact Sciences (EXAS) Acquisition appeared first on CoinCentral.